IO Targets and Combinations

Unlocking Combination Strategies Across the Cancer Immunity Cycle with Advanced IO Models

Work around the cancer immunity cycle with comprehensive capabilities across in vitro, in vivo, ex vivo, and in silico platforms under one roof, designed to support Immuno-Oncology (IO) research. Our versatile platform includes immunocompetent, humanized, or patient-derived models, such as organoids, PDX, and advanced IO models. We offer robust and complementary biomarker analysis, enabling the identification of predictive biomarkers and optimizing therapeutic windows. By focusing on critical IO targets, such as PD-1/PD-L1, and combination strategies involving potentially predictive biomarkers, this service accelerates drug development and empowers next-generation breakthroughs across the drug discovery pipeline.

Four integrated workflows to tackle key challenges

For therapies targeting human antigens, the ADC-ICI combination workflow enhances synergy and efficacy.
The POC workflow uses syngeneic models to optimize ICI combinations efficiently.
To overcome resistance, choose engineered models that restore therapy sensitivity.
Patient-derived models workflow delivers clinically relevant insights, ensuring accurate efficacy assessments.

Webinar

A Novel Approach to Overcoming Limitations of T Cell Immunotherapies

Watch Now

Eliminate Bottlenecks with a Complete Testing Platform

This IO toolkit offers a complete suite of platforms including in vitro 2D/3D assays, pharmacology studies, in vivo efficacy models, and multiomics analysis. Designed to support precise immunotherapy development, it enables comprehensive target evaluation, efficacy testing, and biomarker discovery.